reports
OPHTHOTECH CORP. sees a downgrade to Negative on account of less funda...
The independent financial analyst theScreener just lowered the general evaluation of OPHTHOTECH CORP. (US), active in the Pharmaceuticals industry. As regards its fundamental valuation, the title now shows 0 out of 4 stars while market behaviour can be considered risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Negative. As of the analysis date February 1, 2019, the closing price was USD 1.25 and its target pr...
Ophthotech Reports First Quarter 2018 Financial and Operating Results
NEW YORK--(BUSINESS WIRE)-- Ophthotech Corporation (Nasdaq:OPHT) today announced financial and operating results for the first quarter ended March 31, 2018 and provided a business update. “We continue to build on our Zimura program with on-going clinical trials in wet age related macular degeneration (AMD) with patient recruitment completed and topline data expected by the end of 2018, in geographic atrophy secondary to dry AMD where recruitment is on-track for topline data in the second half of 2019 and in autosomal recessiv...
Ophthotech Completes Patient Recruitment in the Phase 2a Clinical Tria...
NEW YORK--(BUSINESS WIRE)-- Ophthotech Corporation (NASDAQ: OPHT) today announced the completion of patient enrollment in its Phase 2a clinical trial of Zimura® (avacincaptad pegol), the Company’s complement factor C5 inhibitor, in patients with wet age-related macular degeneration (AMD). Zimura is administered in combination with Lucentis® (ranibizumab), an anti-vascular endothelial growth factor (anti-VEGF) agent, in treatment naïve patients with wet AMD. A total of 64 patients have been enrolled into this dose-ranging, open-label, ...
Ophthotech Corporation to Report First Quarter 2018 Financial Results ...
NEW YORK--(BUSINESS WIRE)-- Ophthotech Corporation (Nasdaq:OPHT) today announced that it will report its first quarter 2018 financial and operating results on Wednesday, May 9, 2018. Following the announcement, Ophthotech’s management team will host a live conference call and webcast at 8:00 a.m. Eastern Time to discuss the Company’s financial results and provide a general business update. To participate in this conference call, dial 800-239-9838 (USA) or 323-794-2551 (International), passcode 2075643. A live, listen-only ...
Ophthotech to Present at the Cowen and Company 38th Annual Health Care...
NEW YORK--(BUSINESS WIRE)-- Ophthotech Corporation (Nasdaq: OPHT) announced today that Kourous A. Rezaei, M.D., Chief Medical Officer, will present an overview of the Company at the Cowen and Company 38th Annual Health Care Conference in Boston, MA on Tuesday, March 13, 2018 at 9:20 a.m. Eastern Time. Investors and the general public are invited to listen to a live webcast of the presentation on the Events & Presentations section on the Ophthotech website at www.ophthotech.com. An archived replay of the webcast will be availa...
Ophthotech Reports Fourth Quarter and Full Year 2017 Financial and Ope...
NEW YORK--(BUSINESS WIRE)-- Ophthotech Corporation (Nasdaq:OPHT) today announced financial and operating results for the fourth quarter and full year ended December 31, 2017 and provided a business update. The Company also announced today that it has initiated an innovative gene therapy program focused on applying novel gene therapy technology to discover and develop new therapies for ocular diseases. The Company intends to investigate promising gene therapy product candidates and other technologies through collaborations wit...
Ophthotech Targets Gene Therapy to Expand its Orphan and Age-Related R...
NEW YORK--(BUSINESS WIRE)-- Ophthotech Corporation (NASDAQ:OPHT) announced today that the Company has initiated an innovative gene therapy research collaboration focused on applying novel gene therapy technology to discover and develop next-generation therapies for the treatment of ocular diseases. As part of Ophthotech’s strategy, the Company has entered into a series of sponsored research agreements with the University of Massachusetts Medical School and its Horae Gene Therapy Center to utilize their “minigene” therapy approach and ...
Ophthotech Corporation to Report Fourth Quarter and Full Year 2017 Fin...
NEW YORK--(BUSINESS WIRE)-- Ophthotech Corporation (Nasdaq:OPHT) today announced that it will report its fourth quarter and full year 2017 financial and operating results on Tuesday, February 27, 2018. Following the announcement, Ophthotech’s management team will host a live conference call and webcast at 8:00 a.m. Eastern Time to discuss the Company’s financial results and provide a general business update. To participate in this conference call, dial 800-239-9838 (USA) or 323-794-2551 (International), passcode 9171013. A li...
Ophthotech Announces First Patient Enrolled in the Phase 2b Clinical T...
NEW YORK--(BUSINESS WIRE)-- Ophthotech Corporation (NASDAQ:OPHT) announced today that the first patient has been enrolled in the Phase 2b randomized, double-masked, sham-controlled clinical trial assessing the efficacy and safety of Zimura® (avacincaptad pegol), complement C5 inhibitor, in patients with autosomal recessive Stargardt disease (STGD1). STGD1 is an inherited orphan retinal disease causing vision loss during childhood or adolescence. Currently there are no FDA or EMA approved treatment options available for patients with S...
Ophthotech Announces Election of Jane Pritchett Henderson, Chief Finan...
NEW YORK--(BUSINESS WIRE)-- Ophthotech Corporation (NASDAQ: OPHT) announced today the election of Jane Pritchett Henderson, Chief Financial Officer and Senior Vice President of Corporate Development at Voyager Therapeutics, to its Board of Directors, effective immediately. Ms. Henderson has also been elected the Chair of the Ophthotech Audit Committee. “We are excited to have someone of Jane’s caliber join our Board of Directors,” stated David R. Guyer, Executive Chairman of Ophthotech. “Jane’s financial background and corpor...
Ophthotech Corporation to Present at the 36th Annual J.P. Morgan Healt...
NEW YORK--(BUSINESS WIRE)-- Ophthotech Corporation (NASDAQ: OPHT) announced today that Glenn P. Sblendorio, Chief Executive Officer and President, will present an overview of the Company at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 11, 2018 at 8:00 a.m. Pacific Time (11:00 a.m. Eastern Time). Investors and the general public are invited to listen to a live webcast of the presentation at www.ophthotech.com. Please connect to Ophthotech’s website several minutes prior to the ...
Ophthotech Reports Third Quarter 2017 Financial and Operating Results
NEW YORK--(BUSINESS WIRE)-- Ophthotech Corporation (Nasdaq: OPHT) today announced financial and operating results for the third quarter ended September 30, 2017 and provided a business update. “We are very excited to provide an update on the expansion of our age related and orphan retina programs with our complement C5 inhibitor, Zimura,” stated Glenn P. Sblendorio, Chief Executive Officer and President of Ophthotech. “Scientific literature continues to strengthen our belief in the potential role of complement C5 inhibition i...
Ophthotech Corporation to Report Third Quarter 2017 Financial Results ...
NEW YORK--(BUSINESS WIRE)-- Ophthotech Corporation (Nasdaq:OPHT) today announced that it will report its third quarter 2017 financial and operating results on Wednesday, November 8, 2017. Following the announcement, Ophthotech’s management team will host a live conference call and webcast at 8:00 a.m. Eastern Time to discuss the Company’s financial results and provide a business update. To participate in this conference call, dial 800-239-9838 (USA) or +1 323-794-2551 (International), passcode 7300213. A live, listen-only ...
Ophthotech Provides Update on Zimura® Complement Programs for Treatme...
NEW YORK--(BUSINESS WIRE)-- Ophthotech Corporation (NASDAQ: OPHT) announced today the initiation of an open-label Phase 2a clinical trial of Zimura® (avacincaptad pegol), the Company’s complement factor C5 inhibitor, in patients with wet age-related macular degeneration (AMD). Zimura will be administered in combination with Lucentis® (ranibizumab), an anti-vascular endothelial growth factor (anti-VEGF), in patients with wet AMD who have not been previously treated with anti-VEGF drugs. A range of Zimura dosing regimens will be assesse...
Ophthotech Announces Results from Third Phase 3 Trial of Fovista® in ...
NEW YORK--(BUSINESS WIRE)-- Ophthotech Corporation (Nasdaq:OPHT) today announced that the pre-specified primary endpoint of mean change in visual acuity at 12 months was not achieved in its Phase 3 clinical trial investigating the superiority of Fovista® (pegpleranib) anti-PDGF therapy in combination with Eylea® (aflibercept) or Avastin® (bevacizumab) anti-VEGF therapy compared to Eylea® or Avastin® monotherapy for the treatment of wet age-related macular degeneration (AMD). The addition of 1.5mg of Fovista® to an Eylea® or Ava...
Ophthotech Reports Second Quarter 2017 Financial and Operating Results
NEW YORK--(BUSINESS WIRE)-- Ophthotech Corporation (Nasdaq:OPHT) today announced financial and operating results for the second quarter ended June 30, 2017 and provided a business update on its strategic plan. The Company also announced today that it is pursuing a strategy to leverage its clinical experience and retina expertise to identify and develop therapies to treat multiple orphan ophthalmic diseases for which there are limited or no treatment options available. In parallel, the Company is continuing its on-going age-re...
Ophthotech Expands Focus with Development for Ophthalmic Orphan Diseas...
NEW YORK--(BUSINESS WIRE)-- Ophthotech Corporation (Nasdaq:OPHT) today announced that the Company is pursuing a strategy to leverage its clinical experience and retina expertise to identify and develop therapies to treat multiple orphan ophthalmic diseases for which there are limited or no treatment options available. In parallel, the Company continues its ongoing age-related retinal programs and its business development efforts to obtain rights to additional products, product candidates and technologies to treat ophthalmic diseases, ...
Ophthotech Corporation to Report Second Quarter 2017 Financial Results...
NEW YORK--(BUSINESS WIRE)-- Ophthotech Corporation (Nasdaq:OPHT) today announced that it will report its second quarter 2017 financial and operating results on Wednesday, July 26, 2017. Following the announcement, Ophthotech’s management team will host a live conference call and webcast at 8:00 a.m. Eastern Time to discuss the Company’s financial results and provide a business update. To participate in this conference call, dial 888-280-4443 (USA) or 719-457-2603 (International), passcode 8248330. A live, listen-only audio we...
Newman Ferrara LLP Announces Corporate Governance Investigation of Oph...
NEW YORK--(BUSINESS WIRE)-- Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of Ophthotech Corp. (“Ophthotech” or the “Company”) (NASDAQ:OPHT) into potential breaches of fiduciary duty by the Company’s Board of Directors (the “Board”). Ophthotech, headquartered in New York City, NY, is a biopharmaceutical company engaged in the development of therapeutics to treat ophthalmic diseases. Newman Ferrara’s investigation focuses on decisions made by the Board, without shareho...
Ophthotech Reports First Quarter 2017 Financial and Operating Results
NEW YORK--(BUSINESS WIRE)-- Ophthotech Corporation (Nasdaq:OPHT) today announced financial and operating results for the first quarter ended March 31, 2017 and provided a general business update. In February 2017, Ophthotech announced that it had initiated a plan to review its strategic alternatives in order to maximize shareholder value. The principal focus of the plan, based on the Company's deep expertise and experience in ophthalmology, is to actively explore opportunities to obtain rights to additional products, product ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.